"The site inspection of unit-1 was completed on May 10 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP)," Caplin Point Laboratories said in a BSE filing.
The facility is capable of manufacturing liquid injectables in vials, ampoules, lyophilized vials and pre-filled syringes, amongst other dosage forms, it added.
"Colombia is part of our expansion plans into the larger markets of Latin America. It also happens to be our first approval from Unit-1 site at Puducherry. We'll be focusing on niche opportunities in injectables in these newer geographies," Caplin Point Laboratories Chairman C C Paarthipan said.
Caplin Point Laboratories' unit-1 site currently caters to emerging markets of Latin America and Africa with a variety of dosage forms such as tablets, capsules, softgel capsules, suppositories, liquid orals and topicals.
Shares of Caplin Point Laboratories were trading 0.80 per cent lower at Rs 334.40 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)